PATH
Seattle, Washington, United States
Purpose
to advance the development and evaluation of the promising new dmLT adjuvant by ensuring an expanded supply of high-quality clinical-grade material for use in trials designed to further investigate its ability to improve the immunogenicity
Division
Global Health
Date
November 2014
Region Served
GLOBAL
Committed amount
$3,057,630
Grant topic
Vaccine Development
Duration (months)
154
Grantee location
Seattle, Washington, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.